Source: The San Diego Union Tribune

Prometheus Biosciences: Merck paying $10.8B for San Diego biotech that focuses on Crohn's disease, colitis

The deal comes after young biotech reported positive results last year in a mid-stage trial for treatments targeting ulcerative colitis and Crohn's disease.

Read full article »
Prometheus Biosciences's Competitors | Prometheus Biosciences's News | Prometheus Biosciences's Financials
Stay up-to-date with the latest news on Prometheus Biosciences
Annual Revenue
$100K-5.0M
Employees
25-100
Mark C. McKenna's photo - President & CEO of Prometheus Biosciences

President & CEO

Mark C. McKenna

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Prometheus Biosciences